Bexion Pharmaceuticals
Anti-Cancer Technology White Paper: Bexion Pharmaceuticals has contracted with SciComPro-LLC for scientific communications work on an exciting new anti-cancer technology (SapC-DOPS nanovesicles). “We’re delighted to have Dr. Weingand working with the Bexion team”, said Ray Takigiku, CEO of Bexion Pharmaceuticals. Takigiku added, “Kurt’s expertise will really help us communicate our exciting new development results effectively”. Weingand developed a new White paper on SapC-DOPS nanotherapy for Bexion Pharmaceuticals. For more information on this exciting new technology, visit www.bexionpharma.com.
